Benjamin Exter

Benjamin Exter has extensive experience in the field of pharmacovigilance and risk management. Benjamin is currently serving as the Vice President of Pharmacovigilance and Risk Management at Cogent Biosciences since March 2021. Prior to this, they worked as a Senior Consultant at Pharmacovigilance Strategic Services, LLC starting from August 2020.

In the past, Benjamin held various leadership roles at Unum Therapeutics. Benjamin served as the Vice President and Head of Pharmacovigilance and Risk Management from May 2019 to August 2020, and as the Sr. Director of Clinical Sciences from August 2017 to April 2019.

Before joining Unum Therapeutics, Benjamin gained experience at Takeda Pharmaceuticals and Takeda Oncology. At Takeda, they worked as the Sr. Director of Global Pharmacovigilance from November 2016 to August 2017, and as the Director of Global Pharmacovigilance from December 2014 to November 2016.

Prior to their roles at Takeda, Benjamin worked at Biogen Idec as a DSRM Clinical Trials Sr. Associate II from July 2007 to June 2011, and also served as a Postdoctoral Fellow from an unspecified start date to 2009.

Overall, Benjamin Exter possesses a strong background in pharmacovigilance and risk management, with leadership experience in both consulting and pharmaceutical company settings.

Benjamin Exter pursued their education at Northeastern University from 2001 to 2007, where they completed a Pharm. D. degree in the field of Pharmacy. Following this, from 2007 to 2009, they attended the Massachusetts College of Pharmacy and Health Sciences for a Biogen Idec Post-Doctoral Fellowship. During this fellowship, Benjamin focused their studies on Regulatory Affairs, Pharmacovigilance, and Marketing.